Comparison of Noninvasive Hypoxia Imaging with 18F-Fluoroerythronitroimidazole and 18F-Fluoromisonidazole Pet/Ct in Lung Cancer: A Pilot Clinical Study.

Yuchun Wei,Wei Zhao,Yong Huang,Ning Liu,Song Gao,Jinming Yu,Shuanghu Yuan
DOI: https://doi.org/10.1200/jco.2016.34.15_suppl.e20006
IF: 45.3
2016-01-01
Journal of Clinical Oncology
Abstract:e20006 Background: Intratumoral hypoxia increases tumor aggressiveness, chemo- and radio-resistance. This is a clinical study to compare noninvasive hypoxia imaging using 18F-fluoroerythronitroimidazole (18F-FETNIM) and 18F-fluoromisonidazole (18F-FMISO) positron emission tomography/computed tomography (PET/CT) in patients with inoperable stages III–IV lung cancer. Methods: A total of forty-two patients with inoperable stages III–IV lung cancer underwent 18F-FETNIM PET/CT (n = 18) and 18F-FMISO PET/CT (n = 24) before chemo/radiation therapy. The maximum standard uptake value (SUVmax) of malignant and mean standard uptake value (SUVmean) of normal tissues depict 18F-FETNIM PET/CT and 18F-FMISOPET/CT uptake. Tumor-to-blood ratios (T/B) were used to quantify hypoxia. Results: All patients with lung cancer underwent 18F-FETNIM PET/CT and 18F-FMISO PET/CT successfully. Compared to 18F-FMISO, 18F-FETNIM showed similar uptake in muscle, thyroid, spleen, pancreas, heart, lung and different uptake in blood, liver, and kidney. A significantly higher SUVmax and T/B ratio with 18F-FMISO (2.56±0.77, 1.98±0.54), as compared to 18F-FETNIM (2.12±0.56, 1.42±0.33) was seen in tumor, P =0.022, < 0.001. For the patients with different pathological subtypes, no significant difference of SUVmax (or T/B ratio) was observed between 18F-FMISO and 18F-FETNIM in tumor except that a slightly higher T/B ratio with 18F-FMISO as compared to 18F-FETNIM was observed in squamous carcinoma, P =0.026. 18F-FMISO showed a significantly higher T/B ratio or SUVmax than 18F-FETNIM, when the longest tumor diameter is more than 2 cm. 18F-FMISO showed a significantly higher T/B ratio than 18F-FETNIM both in stage III and IV and a significantly higher SUVmax (or T/B ratio) with stage IV as compared to stage III was seen with the two tracers. Conclusions: 18F-FMISO showed significantly higher uptake than 18F-FETNIM in tumors and might be the better hypoxia biomarker in lung cancer.
What problem does this paper attempt to address?